Risk of CVD in patients with VT
| Subjects . | Individuals, n . | Observation-years . | Events, n . | Incidence rate per 1000 py (95% CI) . | Adjusted HR* (95% CI) . | Adjusted HR† (95% CI) . | Adjusted HR‡ (95% CI) . |
|---|---|---|---|---|---|---|---|
| Event of interest: overall CVD | |||||||
| RDD controls | 2638 | 10 166 | 16 | 1.6 (0.9-2.6) | Reference | Reference | Reference |
| Patients | 4480 | 22 423 | 72 | 3.2 (2.5-4.0) | 2.2 (1.2-3.8) | 2.3 (1.2-4.3) | 2.2 (1.2-4.2) |
| DVT | 2635 | 13 022 | 44 | 3.4 (2.5-4.5) | 2.4 (1.3-4.4) | 2.4 (1.2-4.8) | 2.4 (1.2-4.8) |
| PE ± DVT | 1845 | 9402 | 28 | 3.0 (2.0-4.3) | 2.1 (1.1-4.2) | 2.1 (1.0-4.4) | 2.0 (1.0-4.3) |
| Partner controls | 2926 | 16 402 | 36 | 2.2 (1.5-3.0) | Reference | Reference | Reference |
| Patients | 4480 | 22 423 | 72 | 3.2 (2.5-4.0) | 1.5 (1.0-2.3) | 1.6 (1.0-2.4) | 1.5 (1.0-2.4) |
| DVT | 2635 | 13 022 | 44 | 3.4 (2.5-4.5) | 1.6 (1.0-2.6) | 1.7 (1.0-2.7) | 1.6 (1.0-2.7) |
| PE ± DVT | 1845 | 9402 | 28 | 3.0 (2.0-4.3) | 1.4 (0.8-2.3) | 1.5 (0.8-2.6) | 1.4 (0.8-2.5) |
| Event of interest: myocardial infarction | |||||||
| RDD controls | 2633 | 10 157 | 11 | 1.1 (0.5-1.9) | Reference | Reference | Reference |
| Patients | 4462 | 22 363 | 54 | 2.4 (1.8-3.2) | 2.4 (1.2-4.8) | 2.8 (1.2-6.3) | 2.7 (1.2-6.1) |
| DVT | 2626 | 12 993 | 35 | 2.7 (1.9-3.7) | 3.3 (1.6-7.0) | 3.2 (1.4-7.6) | 3.2 (1.4-7.6) |
| PE ± DVT | 1836 | 9370 | 19 | 2.0 (1.2-3.2) | 2.0 (0.8-4.5) | 2.2 (0.9-5.8) | 2.2 (0.8-5.7) |
| Partner controls | 2916 | 16 362 | 26 | 1.6 (1.0-2.3) | Reference | Reference | Reference |
| Patients | 4462 | 22 363 | 54 | 2.4 (1.8-3.2) | 1.6 (1.0-2.6) | 1.6 (1.0-2.8) | 1.6 (1.0-2.7) |
| DVT | 2626 | 12 993 | 35 | 2.7 (1.9-3.7) | 2.0 (1.2-3.3) | 2.0 (1.1-3.5) | 1.9 (1.1-3.4) |
| PE ± DVT | 1836 | 9370 | 19 | 2.0 (1.2-3.2) | 1.2 (0.6-2.3) | 1.3 (0.7-2.6) | 1.3 (0.6-2.5) |
| Event of interest: ischemic stroke | |||||||
| RDD controls | 2627 | 10 149 | 5 | 0.5 (0.2-1.2) | Reference | Reference | Reference |
| Patients | 4427 | 22 258 | 19 | 0.9 (0.5-1.3) | 1.7 (0.6-4.7) | 1.5 (0.5-4.4) | 1.5 (0.5-4.2) |
| DVT | 2601 | 12 916 | 10 | 0.8 (0.4-1.4) | 1.2 (0.4-4.1) | 1.2 (0.4-3.9) | 1.1 (0.3-3.7) |
| PE ± DVT | 1826 | 9341 | 9 | 1.0 (0.4-1.8) | 2.4 (0.8-7.3) | 1.9 (0.6-6.2) | 1.8 (0.5-6.1) |
| Partner controls | 2901 | 16 339 | 11 | 0.7 (0.3-1.2) | Reference | Reference | Reference |
| Patients | 4427 | 22 258 | 19 | 0.9 (0.5-1.3) | 1.3 (0.6-2.7) | 1.3 (0.6-3.0) | 1.2 (0.5-2.8) |
| DVT | 2601 | 12 916 | 10 | 0.8 (0.4-1.4) | 1.0 (0.4-2.4) | 1.1 (0.4-2.9) | 1.0 (0.4-2.7) |
| PE ± DVT | 1826 | 9341 | 9 | 1.0 (0.4-1.8) | 1.7 (0.7-4.0) | 1.7 (0.7-4.3) | 1.6 (0.6-4.1) |
| Subjects . | Individuals, n . | Observation-years . | Events, n . | Incidence rate per 1000 py (95% CI) . | Adjusted HR* (95% CI) . | Adjusted HR† (95% CI) . | Adjusted HR‡ (95% CI) . |
|---|---|---|---|---|---|---|---|
| Event of interest: overall CVD | |||||||
| RDD controls | 2638 | 10 166 | 16 | 1.6 (0.9-2.6) | Reference | Reference | Reference |
| Patients | 4480 | 22 423 | 72 | 3.2 (2.5-4.0) | 2.2 (1.2-3.8) | 2.3 (1.2-4.3) | 2.2 (1.2-4.2) |
| DVT | 2635 | 13 022 | 44 | 3.4 (2.5-4.5) | 2.4 (1.3-4.4) | 2.4 (1.2-4.8) | 2.4 (1.2-4.8) |
| PE ± DVT | 1845 | 9402 | 28 | 3.0 (2.0-4.3) | 2.1 (1.1-4.2) | 2.1 (1.0-4.4) | 2.0 (1.0-4.3) |
| Partner controls | 2926 | 16 402 | 36 | 2.2 (1.5-3.0) | Reference | Reference | Reference |
| Patients | 4480 | 22 423 | 72 | 3.2 (2.5-4.0) | 1.5 (1.0-2.3) | 1.6 (1.0-2.4) | 1.5 (1.0-2.4) |
| DVT | 2635 | 13 022 | 44 | 3.4 (2.5-4.5) | 1.6 (1.0-2.6) | 1.7 (1.0-2.7) | 1.6 (1.0-2.7) |
| PE ± DVT | 1845 | 9402 | 28 | 3.0 (2.0-4.3) | 1.4 (0.8-2.3) | 1.5 (0.8-2.6) | 1.4 (0.8-2.5) |
| Event of interest: myocardial infarction | |||||||
| RDD controls | 2633 | 10 157 | 11 | 1.1 (0.5-1.9) | Reference | Reference | Reference |
| Patients | 4462 | 22 363 | 54 | 2.4 (1.8-3.2) | 2.4 (1.2-4.8) | 2.8 (1.2-6.3) | 2.7 (1.2-6.1) |
| DVT | 2626 | 12 993 | 35 | 2.7 (1.9-3.7) | 3.3 (1.6-7.0) | 3.2 (1.4-7.6) | 3.2 (1.4-7.6) |
| PE ± DVT | 1836 | 9370 | 19 | 2.0 (1.2-3.2) | 2.0 (0.8-4.5) | 2.2 (0.9-5.8) | 2.2 (0.8-5.7) |
| Partner controls | 2916 | 16 362 | 26 | 1.6 (1.0-2.3) | Reference | Reference | Reference |
| Patients | 4462 | 22 363 | 54 | 2.4 (1.8-3.2) | 1.6 (1.0-2.6) | 1.6 (1.0-2.8) | 1.6 (1.0-2.7) |
| DVT | 2626 | 12 993 | 35 | 2.7 (1.9-3.7) | 2.0 (1.2-3.3) | 2.0 (1.1-3.5) | 1.9 (1.1-3.4) |
| PE ± DVT | 1836 | 9370 | 19 | 2.0 (1.2-3.2) | 1.2 (0.6-2.3) | 1.3 (0.7-2.6) | 1.3 (0.6-2.5) |
| Event of interest: ischemic stroke | |||||||
| RDD controls | 2627 | 10 149 | 5 | 0.5 (0.2-1.2) | Reference | Reference | Reference |
| Patients | 4427 | 22 258 | 19 | 0.9 (0.5-1.3) | 1.7 (0.6-4.7) | 1.5 (0.5-4.4) | 1.5 (0.5-4.2) |
| DVT | 2601 | 12 916 | 10 | 0.8 (0.4-1.4) | 1.2 (0.4-4.1) | 1.2 (0.4-3.9) | 1.1 (0.3-3.7) |
| PE ± DVT | 1826 | 9341 | 9 | 1.0 (0.4-1.8) | 2.4 (0.8-7.3) | 1.9 (0.6-6.2) | 1.8 (0.5-6.1) |
| Partner controls | 2901 | 16 339 | 11 | 0.7 (0.3-1.2) | Reference | Reference | Reference |
| Patients | 4427 | 22 258 | 19 | 0.9 (0.5-1.3) | 1.3 (0.6-2.7) | 1.3 (0.6-3.0) | 1.2 (0.5-2.8) |
| DVT | 2601 | 12 916 | 10 | 0.8 (0.4-1.4) | 1.0 (0.4-2.4) | 1.1 (0.4-2.9) | 1.0 (0.4-2.7) |
| PE ± DVT | 1826 | 9341 | 9 | 1.0 (0.4-1.8) | 1.7 (0.7-4.0) | 1.7 (0.7-4.3) | 1.6 (0.6-4.1) |
PE, pulmonary embolism; py, person-years.
Adjusted for anticoagulation therapy.
Adjusted for anticoagulation therapy, age, sex, BMI, and smoking.
Adjusted for anticoagulation therapy, age, sex, BMI, smoking, chronic disease (defined as liver disease, kidney disease, multiple sclerosis or rheumatoid arthritis), and malignancy.